Vaxcyte, Inc. (PCVX)

Market Cap	6.57B
Revenue (ttm)	n/a
Net Income (ttm)	-402.27M
Shares Out	108.76M
EPS (ttm)	-4.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,784
Open	60.32
Previous Close	60.06
Day's Range	59.41 - 60.76
52-Week Range	41.60 - 82.04
Beta	0.89
Analysts	Strong Buy
Price Target	89.50 (+47.5%)
Earnings Date	May 10, 2024

About PCVX

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 254
• Stock Exchange: NASDAQ
• Ticker Symbol: PCVX

Analyst Forecast

According to 4 analysts, the average rating for PCVX stock is "Strong Buy." The 12-month stock price forecast is $89.5, which is an increase of 47.50% from the latest price.

Price Target

$89.5

(47.50% upside)

Analyst Consensus: Strong Buy